*Department of Obstetrics and Gynecology, College of Medicine, Seoul National University; †Department of Obstetrics and Gynecology, Inje University Sanggye Paik Hospital; and ‡Departments of Medicine, and §Pathology, Seoul National University College of Medicine, Seoul, Korea.
Int J Gynecol Cancer. 2014 Feb;24(2):289-94. doi: 10.1097/IGC.0000000000000063.
The aim of this study was to compare the survival outcomes of adenosquamous carcinoma (ASC) and adenocarcinoma (AC) of the cervix.
We searched PubMed and Embase for observational studies that compared the outcomes of 2 histologic subtypes. Hazards ratios (HRs) with 95% confidence intervals (CIs) were calculated with a fixed effects model.
A total of 17 studies were included in the analyses. Patients with ASC were associated significantly with poorer overall survival (death HR, 1.27; 95% CI, 1.12-1.43; I(2) = 0%) and recurrence-free survival (recurrence HR, 1.43; 95% CI, 1.05-1.95; I(2) = 19.4%) than those with AC. For clinical stages I and II in particular, ASC predicted significantly poorer outcomes compared with AC (death HR, 1.41; 95% CI, 1.17-1.70; I(2) = 0%).
This meta-analysis suggests that ASC may have poorer outcomes compared with AC of the cervix.
本研究旨在比较宫颈的腺鳞癌（ASC）和腺癌（AC）的生存结局。
我们在 PubMed 和 Embase 中检索了比较 2 种组织学亚型结局的观察性研究。采用固定效应模型计算风险比（HR）及其 95%置信区间（CI）。
共有 17 项研究纳入分析。与 AC 相比，ASC 患者的总生存（死亡 HR，1.27；95%CI，1.12-1.43；I²=0%）和无复发生存（复发 HR，1.43；95%CI，1.05-1.95；I²=19.4%）显著较差。特别是对于临床分期 I 和 II，与 AC 相比，ASC 显著预示着更差的结局（死亡 HR，1.41；95%CI，1.17-1.70；I²=0%）。
这项荟萃分析表明，与宫颈的 AC 相比，ASC 可能具有更差的结局。
